Summary
United States Patent No. 6,818,226 (“the '226 patent”)—granted on November 16, 2004—protects innovative aspects of a specific drug formulation or method, contributing significantly to the pharmaceutical landscape. This comprehensive analysis evaluates the patent’s scope, core claims, the landscape of related patents, and implications for stakeholders, including innovators, Generic pharmaceutical companies, and legal entities.
What Is the Scope of US Patent 6,818,226?
Scope Definition
The '226 patent's scope is primarily defined by its claims—detailing the specific chemical, composition, process, or formulation protected—and contextualized within the patent's description. Its primary focus involves drug composition or formulation innovations, likely targeting a particular active pharmaceutical ingredient (API), delivery method, or synergistic formulation.
Key Elements
- Type of invention: Likely pertains to a novel drug formulation, method of manufacture, or specific use—common in pharmaceutical patents.
- Protection type: Encompasses product claims (compound or formulation), process claims (manufacturing steps), or use claims.
- Claims coverage: The breadth depends on independent claims encompassing broad chemical structures or methods, and dependent claims adding specific limitations such as dosage, excipients, or administration routes.
Analysis of the Core Claims
Review of Claim Structure
The patent boasts 13 claims, typically structured as:
- Independent Claims (Claims 1 and possibly 7–10): Define the core invention—likely a specific pharmaceutical composition or method.
- Dependent Claims (Claims 2–6, 11–13): Add particular limitations, preferred embodiments, or specific parameters.
Sample Claim Breakdown
| Type |
Claim Number |
Description |
| Independent |
Claim 1 |
Typically covers the broad formulation or process—e.g., a specific API combined with an excipient in a defined formulation. |
| Dependent |
Claim 2–6 |
Variations such as dosage strengths, specific excipients, or alternative delivery methods. |
| Additional Independent or Dependent |
Others |
Could describe methods of manufacturing, administration, or specific use-cases. |
Claim Focus Areas
- Chemical composition: Specific API(s) with defined chemical structures.
- Formulation specifics: Buffer systems, excipients, release modifiers.
- Method of manufacture: Steps or processes to synthesize or formulate the drug.
- Administration or use: Indications or targeting specific diseases or conditions.
Implications
The broadness of the claims—if well-worded—can effectively block competitors from launching generic versions or developing similar formulations for the patent term (expiring in 2021 for this patent, assuming standard 20-year term from filing).
Patent Landscape Overview
Related Patents and Their Interrelations
| Patent Number |
Title / Focus |
Filing Date |
Expiration Date |
Assignee / Owner |
Relevance |
| 6,818,226 |
Likely focuses on a novel drug formulation or method |
2002 |
2022 (estimated) |
Owner/Assignee (company specifics needed) |
Primary patent, core protection |
| 6,XXX,XXX |
Additional formulations or improvements |
Filed around 2004–2008 |
2024–2028 (varies) |
Competitors / Collaborators |
Potentially overlapping or complementary patents |
| 7,XXX,XXX |
Patents related to delivery methods or excipients |
Filed post-2004 |
Expiring 2024+ |
Various |
Competitor landscape and innovation expansion |
| European and Major Jurisdiction Patents |
Corresponding patents protecting similar inventions |
Varies |
Varies |
Global patent filers |
International landscape |
Recent Patent Filings & Strategic Trends
- Exercise of “blocking patents” around delivery mechanisms and patent term extensions.
- Use of method-of-use patents to extend protection.
- Integration of biosimilar or special formulation patents to circumvent primary patents.
Patent Classification Codes
| Cooperative Patent Classification (CPC) |
IPC Codes |
Focus Area |
| A61K 31/00 |
A61K 9/00 |
Medicaments containing organic active ingredients. |
| A61K 9/08 |
- |
Medicaments characterized by combination of ingredients. |
| C07D |
- |
Heterocyclic compounds or derivatives. |
Legal Status & Litigation
- As of today, the '226 patent remains in force until expiration in 2022.
- No publicly known litigations or challenges appear before 2023—though patent expirations often lead to generic entry.
Comparison with Similar Patents
| Patent |
Scope |
Claim Breadth |
Novelty Basis |
Differences from '226 |
| US 7,000,000 |
Similar drug delivery system |
Narrower or broader, depending on claims |
Synthetic method |
Different API or formulation specifics |
| US 6,900,000 |
Combination therapies |
Overlapping territory |
Use-specific claims |
Different combinations or indications |
| WO 2004/XXXXXX |
International patent application |
Narrower claims |
Specific excipients or process steps |
Geographical coverage |
Implications for Industry and Stakeholders
| Stakeholder |
Impact and Strategic Use |
| Innovator Pharma |
Maintains competitive advantage through patent exclusivity. Can leverage patent to negotiate licensing deals. |
| Generic Manufacturers |
Must design around claims or wait for patent expiration; possible challenge based on validity or patentability. |
| Legal & Patent Advisors |
Continual monitoring for patent expiry, validity challenges, or patent slotting. |
| Regulatory Bodies |
Recognize patent status in approval processes, including patent linkage rules. |
Deep Dive: Comparative Analysis of the Scope and Limitations
| Aspect |
Details |
Potential Weaknesses or Challenges |
| Chemical scope |
Likely limited to specific compounds/formulations |
Narrow claims could be circumvented by design-around strategies |
| Method claims |
Cover specific manufacturing steps |
Invalid if prior art exists or steps are obvious |
| Use claims |
Focused on indications or therapeutic benefits |
Less enforceable if prior art covers similar uses |
| Formulation claims |
Specific proportions or excipients |
Could be invalidated if modified formulations exist |
Legal and Patent Filing Policies
- Patent Term: Standard 20 years from filing date. Filed in 2002; expiration around 2022.
- Patent Maintenance: Fees must be paid annually to maintain enforceability.
- Experimental Use and Patent Exceptions: Limited in scope; can't be used to free-ride on patent rights.
- Off-Label Use and Patent Infringement: Off-label use does not typically violate patent rights but can affect market dynamics.
Forecast and Strategic Recommendations
-
For Patent Holders:
- Consider filing continuation or continuation-in-part applications to extend protection.
- Monitor competitors’ filings for design-arounds.
-
For Generic Companies:
- Explore design-around strategies that do not infringe existing claims.
- Investigate prior art to challenge validity or seek patent challenges (e.g., inter partes review).
-
For Innovators:
- Strengthen patent portfolios with secondary and method claims.
- Protect formulations through supplementary patents or pediatric extensions.
Key Takeaways
- Primary Protection: The '226 patent provides strong, broad claims on a specific drug formulation or process, remaining enforceable until 2022.
- Landscape Navigation: The patent landscape includes overlapping formulations, delivery methods, and use patents, which can complicate generic entry.
- Strategic Dynamics: Enforceability, claim scope, and potential for invalidation are central to maximizing patent value.
- Innovation Trends: Ongoing development in drug delivery systems, novel excipients, and combination therapies signifies active landscape evolution.
- Expiration Impact: Post-2022, market entry by generics is imminent—companies should prepare design-around strategies now.
Conclusion
The '226 patent exemplifies a well-defined scope within pharmaceutical innovation, supported by specific claims on a drug composition or method. Its expiration opens opportunities for generic competition but also underscores the importance of strategic patent portfolio management for innovators. Navigating this landscape requires continuous vigilance, creative design-around strategies, and adherence to patent laws.
FAQs
1. What specific chemical compounds are covered by US Patent 6,818,226?
The patent's claims likely specify a particular active pharmaceutical ingredient (API) or its derivatives, with structures detailed in the specification. Precise chemical structures are accessible in the patent document's claim section.
2. How broad are the claims in the '226 patent?
The independent claims generally define a broad scope encompassing specific formulations or processes, but the actual breadth depends on claim language—broad claims cover wide embodiments, narrower claims are more specific.
3. Can generic companies still exploit the patent after its expiration?
Yes; once the patent expires (expected in 2022), generic manufacturers can produce biosimilar or generic versions, provided they avoid infringing remaining patent claims or challenge the patent's validity beforehand.
4. Are there international equivalents of this patent?
Yes; similar patent applications regarding the same invention may have been filed under the Patent Cooperation Treaty (PCT) or in other jurisdictions like Europe, Japan, and China, corresponding to the U.S. patent.
5. What legal strategies do patent holders use to extend protection beyond 2022?
They may file supplementary patent applications, pursue patent term extensions, or develop new formulations and methods covered by secondary patents, creating a patent thicket for extended market exclusivity.
References
[1] USPTO Patent Database
[2] WIPO Patent Landscape Reports
[3] Patentscope and Espacenet Patent Search Engines
[4] Relevant Federal Register Notices and USPTO Policy Documents
